| Literature DB >> 29513726 |
Sloane K Tilley1, Elizabeth M Martin1, Lisa Smeester1, Robert M Joseph2, Karl C K Kuban3, Tim C Heeren4, Olaf U Dammann5, T Michael O'Shea6, Rebecca C Fry1,7.
Abstract
BACKGROUND: The placenta is the central regulator of maternal and fetal interactions. Perturbations of placental structure and function have been associated with adverse neurodevelopmental outcomes later in life. Placental CpG methylation represents an epigenetic modification with the potential to impact placental function, fetal development and child health later in life. STUDYEntities:
Mesh:
Year: 2018 PMID: 29513726 PMCID: PMC5841757 DOI: 10.1371/journal.pone.0193271
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subject characteristics.
Maternal demographic data, pregnancy characteristics, and data on birth and later in life outcomes are presented for the ELGAN subjects used in this analysis. Data are presented as the number (%) of subjects in the cohort unless otherwise noted.
| Characteristic | N = 25 | N = 59 | Student 2-sided t-test p-value (indicated vs. spontaneous EPTB) | N = 1506 |
|---|---|---|---|---|
| 28.89 (17.0–40.5) | 29.5 (16.0–39.4) | 0.89 | 28.5 (13.2–47.3) | |
| 0.48 | ||||
| White | 11 (44.0%) | 27 (45.8%) | 866 (57.4%) | |
| African-American | 9 (36.0%) | 27 (45.8%) | 427 (28.3%) | |
| Other | 5 (20.0%) | 5 (8.5%) | 187 (12.4%) | |
| Unknown | 0 (0.0%) | 0 (0.0%) | 26 (1.7%) | |
| 26.7 (15.2–43.2) | 23.1 (18.6–72.1) | 0.82 | 24.0 (13.2–72.1) | |
| 0.31 | ||||
| No | 16 (64.0%) | 30 (50.8%) | 841 (55.7%) | |
| Yes | 9 (36.0%) | 28 (49.2%) | 594 (39.3%) | |
| Unknown | 0 (0.0%) | 1 (1.7%) | 71 (5.0%) | |
| 0.71 | ||||
| < = 12 years | 5 (20.0%) | 10 (19.9%) | 242 (16.0%) | |
| 12–15 years | 10 (40.0%) | 33 (55.9%) | 731 (48.4%) | |
| 16+ years | 10 (40.0%) | 14 (28.8%) | 428 (28.3%) | |
| Unknown | 0 (0.0%) | 2 (3.4%) | 105 (9.9%) | |
| 0.21 | ||||
| No | 23 (92.0%) | 47 (79.7%) | 1212 (80.3%) | |
| Yes | 2 (8.0%) | 10 (16.9%) | 212 (14.0%) | |
| Unknown | 0 (0.0%) | 2 (3.4%) | 82 (5.7%) | |
| Yes | - | - | 271(17.99%) | |
| No | - | - | 1235 (82.01^) | |
| 0.12 | ||||
| Male | 14 (56.0%) | 44 (74.6%) | 799 (53.1%) | |
| Female | 11 (44.0%) | 15 (25.4%) | 707 (46.9%) | |
| 26.5 (23.5–27.5) | 25.3 (23.6–27.6) | 0.01 | 26.0 (23.0–27.6) | |
| 640 (472–1025) | 787 (544–1260) | 1.28e-3 | 790 (99–1528) | |
| Normal | 4 (16.0%) | 12 (20.3%) | 300 (34.3%) | |
| Low-Normal | 8 (32.0%) | 15 (25.4%) | 360 (41.1%) | |
| Moderately Impaired | 8 (32.0%) | 14 (23.7%) | 145 (16.6%) | |
| Severely Impaired | 5 (20.0%) | 18 (30.5%) | 69 (7.9%) | |
| Unknown | 0 (0.0%) | 0 (0.0%) | 632 (62%) | |
| 5 (1–8) | 5 (1–9) | 0.91 | 5 (0–9) | |
| 7 (3–9) | 7 (2–9) | 0.90 | 7 (0–10) | |
Fig 1(a) Heatmap of 250 DMPs between placentas from indicated EPTB (n = 25) and spontaneous EPTB (n = 59). Beta-values were mean standardized and red indicates increased methylation levels, while blue indicates decreased methylation levels. Significance was defined as FDR q-value < 0.05 and an absolute beta difference ≥ |0.10|. (b) Intragene probe site distribution for all annotated probes (n = 286,410) contained on the Illumina HumanMethylation450 BeadChip. (c) Intragene probe site distribution for 250 DMPs between placentas from indicated EPTB (n = 25) and spontaneous EPTB (n = 59). The distribution of DMPs associated with intrauterine inflammation contained more probes located within the body region of genes and less probes located within the TSS200 region of genes than would be expected from a random sample of the total probe distribution, as indicated (*).
Enriched canonical pathways among the 217 DMP-associated genes.
| Canonical Pathways Enriched Among N = 217 DMP-Associated Genes | p-value (IPA) | p-value (GSEA) | q-value (GSEA) | Associated Genes |
|---|---|---|---|---|
| UDP-N-acetyl-D-galactosamine Biosynthesis II | 1.51E-04 | 5.36 E-5 | 4.75 E-3 | |
| CXCR4 Signaling | 2.63E-04 | 7.18 E-6 | 1.91 E-3 | |
| Cholecystokinin/Gastrin-mediated Signaling | 5.37E-04 | 1.04 E-5 | 2.24 E-3 | |
| Protein Kinase A Signaling | 5.89E-04 | 1.15 E-3 | 3.41 E-2 | |
| Endothelin-1 Signaling | 6.03E-04 | 1.18 E-5 | 2.24 E-3 | |
| Phospholipase C Signaling | 6.61E-04 | 6.84 E-7 | 4.55 E-4 | |
| Trehalose Degradation II (Trehalase) | 9.77E-04 | 1.47 E-4 | 9.32 E-3 |
Transcription factors with enriched binding sites among 250 DMPs.
The most transcription factors with enriched binding sites among the 250 DMPs associated with spontaneous preterm deliveries due to intrauterine inflammation. The p-value was derived from a Z-score representing the overrepresentation of individual transcription factor binding sites and enrichment for individual transcription factor matrices compared against genomic background.
| Transcription Factors with Overrepresentation of Binding Sites Among N = 250 DMPs | P-value | Associated Genes |
|---|---|---|
| BHLHB2 | 8.34e-23 | |
| TCFAP2B | 3.25e-22 | |
| HELT | 3.05e-18 | |
| HRE | 1.17e-15 | |
| USF | 3.66e-15 | |
| DEC1 | 3.99e-15 | |
| NMYC | 7.97E-15 | |
| ARNT | 7.97E-15 |
* Indicates a bHLH transcription factor.
Fig 2A total of 17 probe sites where increased placental CpG methylation predicted more severe cognitive impairment at ten years of age.
These sites corresponded to 16 unique genes. The model represents the increase in the odds of moderate or severe cognitive impairment at age ten for every one percent increase in methylation at the probe site. Significance was defined as a p-value < 0.05 in a logistic regression model.